Aldeyra's dry eye drug helps with redness but misses other important phase 2 goals.

Aldeyra Therapeutics' dry eye drug helped relieve ocular redness in a phase 2 trial but merely "approached statistical significance" on a secondary endpoint of wetness in the eye. We know you're here for the unspun version of this story, and this is it: the secondary goal was not met. [ABSTRACT FROM AUTHOR]